All In Biotech

Drug Trial Radar · NCT00211978

EPIC(Effect of PhosLo on Phosphorus Levels in Chronic Kidney Disease)

EPIC (Effect of PhosLo on Phosphorus Levels in Chronic Kidney Disease): A Prospective, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel Arm, Study of PhosLo on Phosphorus Levels in Subjects With Chronic Kidney Disease

Last checked: Nov 20, 2026Latest source record: Jan 8, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 110 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

110

Actual

Start

May 2005

Primary completion

Jun 2006

Study completion Oct 2006

Sponsor

Lead sponsor
Nabi BiopharmaceuticalsIndustry
Sponsor type
Industry
First posted
Sep 21, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if calcium acetate (PhosLo) can control serum phosphorus in pre-dialysis patients with moderate to severe impairment of kidney function.

Conditions

  • Hyperphosphatemia
  • Kidney Failure

Interventions

  • calcium acetateDrug

    667 mg gelcaps, 1-3 t.i.d. (titrated to serum phosphorus level)

  • placeboDrug

    gelcap, 1-3 t.i.d. (titrated to serum phosphorus level)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. serum phosphorusTime frame: weeks 5-24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Texas Health Sciences Center

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.